Biobohemia, Inc. is a biotechnology company focused on development of cancer vaccines.
Biobohemia's lead technology is cell Antigenic Essence production via proteomics and cell culture technology, and which is a deep upgrade of cellular cancer vaccines. Antigenic essence technology is the revitalization of cellular vaccination, as antigenic essence exhibits all the identifying properties of cancer cells while also allowing for control of composition, purification from ballast substances (cellular 'noise'), and evasion of MHC restrictions. Therefore, antigenic essence technology allows upgading of already discovered cellular compositions, as well as creation new ones.
Our antigenic essence technology platform is behind the development of the potential candidates for cancer vaccine, under the brand name SANTAVACTM, that can be tuned against virtually any solid cancer. Our company is progressing the development of both prevention and therapeutic SANTAVACTM vaccines.